Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | KRAZATI (adagrasib) (KRYSTAL-17) | 1L Non-small Cell Lung Cancer | Phase 3 | Ongoing | Oral | Oncology |
| Bristol-Myers Squibb Company | Nivolumab - (CheckMate 577) | Esophageal or gastroesophageal junction cancer (EC/GEJC) | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Iberdomide | Lupus Erythematosus (SLE) | Phase 2 | Trial Completed | Oral | Immunology |
| Bristol-Myers Squibb Company | Camzyos (mavacamten) - (ODYSSEY-HCM) | Non-obstructive hypertrophic cardiomyopathy (HCM) | Phase 3 | Ongoing | Oral | Cardiology |
| Bristol-Myers Squibb Company | Sitravatinib and OPDIVO (nivolumab) | Urothelial Carcinoma (Bladder) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Sitravatinib and Opdivo (Nivolumab) - (MRTX-500) | Nonsquamous (NSQ) Non–Small-Cell Lung Cancer (NSCLC) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMS-986446 (PRX005) - (TargetTau-1) | Alzheimer’s disease | Phase 2 | Ongoing | Intravenous | Neurology |
| Bristol-Myers Squibb Company | Deucravacitinib - (PAISLEY) | Moderate to severe systemic lupus erythematosus (SLE) | Phase 2 | Trial Completed | Oral | Immunology |
